Volume 38, Issue 5 1 pp. 1070-1076
Article

A Simple Risk Score to Predict the Presence of Non-Sentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node

Raquel F. D. van la Parra

Corresponding Author

Raquel F. D. van la Parra

Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

[email protected]Search for more papers by this author
Petronella G. M. Peer

Petronella G. M. Peer

Department for Health Evidence, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Search for more papers by this author
Wilfred K. de Roos

Wilfred K. de Roos

Department of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands

Search for more papers by this author
Miranda F. Ernst

Miranda F. Ernst

Department of Surgery, Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands

Search for more papers by this author
Johannes H. W. de Wilt

Johannes H. W. de Wilt

Department of Surgery, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Search for more papers by this author
Koop Bosscha

Koop Bosscha

Department of Surgery, Jeroen Bosch Hospital, ’s-Hertogenbosch, The Netherlands

Search for more papers by this author
First published: 05 December 2013
Citations: 9

Abstract

Background

Historically, completion axillary lymph node dissection (cALND) is recommended in sentinel lymph node (SLN)-positive patients. However, the high rate of negative non-sentinel nodes (NSNs) in cALND and the reported low axillary recurrence rates have led to a more conservative approach. A risk score was developed to identify a patient’s individual risk for NSN metastases.

Methods

Data of 182 SLN-positive patients who underwent cALND were used for risk score development. The risk score, consisting of pathological tumor size (≤20/>20 mm), lymphovascular invasion (no/yes), extracapsular extension (no/yes), size of metastases (≤2/>2 mm), and number of positive SLNs (1/>1), was subsequently validated on an external population (n = 180).

Results

The area under the receiver operating characteristic curve was 0.78 (95 % CI 0.71–0.85) in the original population and 0.78 (95 % CI 0.70–0.85) in the validation population. Based on the predicted risk for positive NSNs, three groups were defined: low risk (≤20 %), intermediate risk (21–50 %), and high risk (>50 %). In total, 88 patients met the Z0011 inclusion criteria and none of them had a high predicted risk. Of the 199 non-Z0011 patients, 67 (33.7 %) had low risk, 96 (48.2 %) had intermediate risk, and 36 (18.1 %) had high risk.

Conclusion

A simple risk score, integrating just five clinicopathological variables, was developed that may assist in individual decision making regarding ALND in SLN-positive patients outside of the Z0011 trial.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.